Colleen Bejot

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
8050 Background: Prognostic models in MCL are still debated particularly in dose-intensive treatment approaches (R-HyCVAD or HDT/ASCT) since they include both age (med age dx, mid 60s) and(More)
  • 1